MCRB - Seres Therapeutics, Inc.
6.92 0.00 (0.00%)
After hours: 4:39PM EDT
| Previous Close | 6.90 |
| Open | 6.87 |
| Bid | 6.90 x 900 |
| Ask | 6.93 x 1000 |
| Day's Range | 6.64 - 6.95 |
| 52 Week Range | 4.42 - 9.75 |
| Volume | 59,935 |
| Avg. Volume | 370,008 |
| Market Cap | 284.055M |
| Beta (3Y Monthly) | 2.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.43 |
| Earnings Date | Mar 6, 2019 - Mar 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.00 |
- Business Wire•20 days ago
Seres Therapeutics Presents New Preclinical Data Supporting the Development of SER-401 for Immuno-Oncology at the 2019 American Association for Cancer Research Annual Meeting
“The novel data presented at AACR provide mechanistic insights into the biological activity of our microbiome therapeutic candidates to augment immune checkpoint inhibitors,” said Matthew Henn, Ph.D., Chief Scientific Officer and Executive Vice President at Seres. Seres presented preclinical results evaluating the impact of various consortia of bacterial species on the anti-tumor immune response in murine models following treatment with an anti-PD-1 checkpoint inhibitor.
- Thomson Reuters StreetEvents•last month
Edited Transcript of MCRB earnings conference call or presentation 6-Mar-19 1:30pm GMT
Q4 2018 Seres Therapeutics Inc Earnings Call
- Zacks•last month
Seres Therapeutics (MCRB) in Focus: Stock Moves 6.7% Higher
Seres Therapeutics (MCRB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
- Schaeffer's Investment Research•last month
Seres Therapeutics Options Volume Peaks After AstraZeneca News
The two companies announced a three-year research collaboration
- Motley Fool•last month
Here's Why Seres Therapeutics Stock Soared Today
A new collaboration with AstraZeneca could give microbiome-based medicine a big lift.
- American City Business Journals•last month
Seres teams up with AstraZeneca to explore microbiome benefits in cancer treatment
Microbiome-focused biotech Seres Therapeutics is teaming up with drug giant AstraZeneca to explore how the trillions of bacteria in a person’s gut could help fight cancer.
- Business Wire•last month
Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration with AstraZeneca
- Collaboration focused on further elucidating the potential of microbiome therapeutics to augment immuno-oncology treatment for cancer –
Motley Fool•2 months agoSeres Therapeutics Inc (MCRB) Q4 2018 Earnings Conference Call Transcript
MCRB earnings call for the period ending December 31, 2018.
- Business Wire•2 months ago
Seres Therapeutics Reports Fourth Quarter and Full Year Financial Results and Provides Operational Updates
- Initiated SER-287 Phase 2b study in mild-to-moderate ulcerative colitis -
- Business Wire•2 months ago
Seres Therapeutics to Present at Three Upcoming March Conferences
Seres Therapeutics, Inc. today announced that it will present at each of the following upcoming healthcare conferences:
- Business Wire•2 months ago
Seres Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Operational Progress Conference Call and Webcast on March 6, 2019
Seres Therapeutics, Inc. today announced that management will host a conference call and live audio webcast on March 6, 2019 at 8:30 a.m. ET to discuss fourth quarter and full year 2018 results and provide a general business update.
- Business Wire•2 months ago
Seres Therapeutics Announces Corporate Changes to Focus on Advancing Clinical Assets
“We believe that microbiome therapeutics have an important role in the future of medicine for a range of serious diseases and that Seres is well positioned to drive progress in the field with our late-stage clinical-stage programs, differentiated drug discovery and state-of-the-art manufacturing capabilities. Following a comprehensive review of our pipeline, we are concentrating our resources on obtaining clinical results from our highest-priority, late-stage clinical programs in ulcerative colitis and C. difficile infection as well as our soon-to-be initiated Phase 1b study in patients with metastatic melanoma,” said Eric Shaff, President and Chief Executive Officer of Seres Therapeutics.
- Business Wire•3 months ago
Seres Therapeutics Announces Chief Executive Officer Transition
Mr. Shaff, who is currently Chief Operating and Financial Officer, succeeds Roger J. Pomerantz, M.D. Mr. Shaff has also joined Seres’ Board of Directors and will continue to serve as Seres’ principal financial officer on an interim basis. Dr. Pomerantz will continue as Chairman of Seres’ Board of Directors.
- Simply Wall St.•4 months ago
Does Seres Therapeutics, Inc.’s (NASDAQ:MCRB) CEO Salary Compare Well With Others?
Roger Pomerantz has been the CEO of Seres Therapeutics, Inc. (NASDAQ:MCRB) since 2014. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
- Business Wire•4 months ago
Seres Therapeutics Announces Initiation of SER-287 Phase 2B ECO-RESET Clinical Study for Ulcerative Colitis
“Advancing SER-287 into a late stage Phase 2B trial is a significant achievement,” said Kevin Horgan, M.D., Executive Vice President and Chief Medical Officer. “We are hopeful that SER-287 may provide individuals with ulcerative colitis with a novel microbiome-based, non-immunosuppressive therapy that addresses the underlying pathology of this serious disease. The SER-287 Phase 2B ECO-RESET study has been designed as a pivotal trial.
- GlobeNewswire•5 months ago
Research Report Identifies OraSure Technologies, Sierra Wireless, Seres Therapeutics, Lydall, ChromaDex, and Capricor Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of MCRB earnings conference call or presentation 8-Nov-18 1:30pm GMT
Q3 2018 Seres Therapeutics Inc Earnings Call
- Business Wire•5 months ago
Seres Therapeutics to Present at the Stifel 2018 Healthcare Conference
Seres Therapeutics, Inc. today announced that it will present at the Stifel 2018 Healthcare Conference in New York, NY on Tuesday, November 13th at 9:30 a.m. ET.
- Zacks•5 months ago
Seres Therapeutics (MCRB) Reports Q3 Loss, Misses Revenue Estimates
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 5.26% and -61.35%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire•5 months ago
Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational Updates
- Kevin Horgan, M.D. an accomplished drug developer and immunology expert, hired as Chief Medical Officer -
- Business Wire•6 months ago
Seres Therapeutics to Host Third Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2018
Seres Therapeutics, Inc. today announced that management will host a conference call and live audio webcast on November 8, 2018 at 8:30 a.m. ET to discuss third quarter 2018 results and provide a general business update.
- Business Wire•6 months ago
Seres Therapeutics Announces Appointment of Kevin Horgan, M.D., as Chief Medical Officer
Dr. Horgan will lead Seres’ clinical development, clinical operations, regulatory affairs, and medical affairs functions. Dr. Horgan will succeed Seres’ outgoing Chief Medical Officer, Michele Trucksis, Ph.D., M.D., who will continue to provide consulting services to the Company.
- Zacks•6 months ago
Seres Therapeutics Sees Hammer Chart Pattern: Time to Buy?
Seres Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
- Business Wire•7 months ago
Seres Therapeutics to Present New Data Supporting SER-109 Clinical Activity at IDWeek 2018
Findings support SER-109 Phase 3 program as a potential new treatment option for C. difficile infection
